REXAHN PHARMACEUTICALS INC's ticker is RNN and the CUSIP is 761640101. A total of 18 filers reported holding REXAHN PHARMACEUTICALS INC in Q4 2013. The put-call ratio across all filers is - and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2017 | $42,000 | +320.0% | 82,391 | +20.3% | 0.00% | – |
| Q4 2016 | $10,000 | -28.6% | 68,500 | 0.0% | 0.00% | – |
| Q3 2016 | $14,000 | -17.6% | 68,500 | -1.2% | 0.00% | – |
| Q2 2016 | $17,000 | -26.1% | 69,312 | 0.0% | 0.00% | – |
| Q1 2016 | $23,000 | +91.7% | 69,312 | +118.3% | 0.00% | – |
| Q4 2015 | $12,000 | -29.4% | 31,748 | 0.0% | 0.00% | – |
| Q3 2015 | $17,000 | 0.0% | 31,748 | +14.3% | 0.00% | – |
| Q2 2015 | $17,000 | -15.0% | 27,783 | 0.0% | 0.00% | – |
| Q1 2015 | $20,000 | +5.3% | 27,783 | +0.5% | 0.00% | – |
| Q4 2014 | $19,000 | +18.8% | 27,658 | +39.3% | 0.00% | – |
| Q3 2014 | $16,000 | -72.4% | 19,860 | -70.0% | 0.00% | – |
| Q2 2014 | $58,000 | -26.6% | 66,123 | -9.1% | 0.00% | – |
| Q1 2014 | $79,000 | +276.2% | 72,733 | +74.2% | 0.00% | – |
| Q4 2013 | $21,000 | +16.7% | 41,755 | +6.3% | 0.00% | – |
| Q3 2013 | $18,000 | +5.9% | 39,286 | 0.0% | 0.00% | – |
| Q2 2013 | $17,000 | – | 39,286 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| SABBY MANAGEMENT, LLC | 2,250,840 | $1,013,000 | 0.07% |
| Benin Management CORP | 83,000 | $38,000 | 0.02% |
| WFG Advisors, LP | 20,000 | $9,000 | 0.00% |
| GOLDMAN SACHS GROUP INC | 40,230 | $19,000 | 0.00% |
| UBS AG | 1,000 | $0 | 0.00% |
| NOMURA HOLDINGS INC | 137,100 | $62,000 | 0.00% |
| GEODE CAPITAL MANAGEMENT, LLC | 276,931 | $125,000 | 0.00% |
| GUGGENHEIM CAPITAL LLC | 39,286 | $18,000 | 0.00% |
| Commonwealth Equity Services, Inc | 33,339 | $15,000 | 0.00% |
| Citadel Advisors | 42,132 | $19,000 | 0.00% |